Pulmonary Hypertension in Mitral Regurgitation

Harsh Patel, MD; Milind Desai, MD; E. Murat Tuzcu, MD; Brian Griffin, MD; Samir Kapadia, MD

Mitral regurgitation (MR) is the most common valvular lesion in the United States and the second-most common valvular lesion requiring surgery in Europe. In the United States, over 2.5 million people are estimated to have moderate-to-severe MR, and this number is expected to double by 2030. Over the past several decades, improvements in our ability to diagnose and quantify MR, coupled with a better understanding of its natural history and the adverse prognostic features, has led to the refinement of indications for mitral valve surgery. Pulmonary hypertension (defined as a systolic pressure >50 mm Hg at rest or >60 mm Hg with exercise) is one such adverse prognostic indicator, the presence of which in patients with asymptomatic MR translates to a class IIA indication for mitral valve surgery according to the latest American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) guidelines. Pulmonary hypertension has long been known to be a serious complication of mitral valve disease (MVD). Yet, its precise role in the natural history and management of patients with MR remains scanty investigated, as exemplified by a level of evidence C associated with the above-mentioned recommendation for surgery.

Pulmonary hypertension associated with MVD was originally reported in patients with rheumatic mitral stenosis, both in isolation and in combination with MR. Early case series of such patients reported a dismal prognosis without surgical intervention as well as high operative mortality with mitral valve replacement. While it was recognized that pulmonary hypertension may also complicate chronic isolated MR, the initial perception was that it was much more common in mitral stenosis. Yet, Alexopoulos et al., in a small single-center study, reported that a variable degree of pulmonary hypertension was present on right heart catheterization in 76% of patients with chronic isolated severe MR with normal left ventricular (LV) function (LVF). Unfortunately, most of the early studies of pulmonary hypertension in MR are limited by having small sample sizes and including patients with varying degrees of MR and pulmonary hypertension. More recently, Barbieri et al. showed, in a multicenter long-term international study, that significant pulmonary hypertension (defined as pulmonary artery systolic pressure [PASP] >50 mm Hg) was present in 23% of patients with severe degenerative MR. Pulmonary hypertension can also frequently complicate the course of patients with chronic functional MR as a result of both systolic and diastolic LV dysfunction. Therefore, the true prevalence of pulmonary hypertension in such patients is not really known.

Pathogenesis of Pulmonary Hypertension in MR

The natural history of chronic severe MR can be divided into three separate phases based on the clinical and hemodynamic profile. During the initial compensated phase, the left ventricle undergoes eccentric hypertrophy as a result of volume overload and develops into a large compliant chamber capable of producing a larger total stroke volume. The left atrium also enlarges and is able to accommodate a large regurgitant volume without significant elevation in mean left atrial pressure (LAP). LV contractile function and pulmonary arterial pressures are normal and the patient remains asymptomatic during this phase. By contrast, the final decompensated phase of chronic MR is characterized by symptoms of heart failure (HF) associated with progressive decline in LV contractile function, maladaptive increase in LV dimensions with resulting increase in systolic wall stress, elevation of left-sided filling pressures, and worsening pulmonary hypertension.

Whereas the compensated and decompensated stages have distinct clinical and hemodynamic features (see Figure 1), the intervening transitional period remains a poorly defined phase in the natural history of chronic MR. Even though the precise factors that determine evolution into the transitional phase remain elusive, it is clear that LV contractile function initially begins to deteriorate during this phase. Ejection fraction (EF) and other load-dependent indices of contractile function may
remain normal or decrease minimally, masking the underlying contractile dysfunction. LAP, which is not substantially elevated in the compensated phase, despite significant regurgitation, may begin to rise as a result of occult LV systolic or diastolic dysfunction and decline in left atrial compliance. As a result, pulmonary hypertension may also begin to develop during this phase.

The processes that govern the development of pulmonary hypertension in MR are multifactorial (see Figure 2) and are not yet fully understood. Elevation of LAP, which occurs not only in acute MR, but also in the transitional and decompensated phases of chronic MR, is believed to be the initiating factor in the pathogenesis of pulmonary hypertension. Sustained elevation of LAP, which is passively transmitted backward into the pulmonary veins, can lead to disruption of the delicate alveolar-capillary complex in a process known as alveolar capillary stress failure, with resulting capillary leakage and pulmonary edema. In the initial phases, this lesion is reversible. However, with long-standing pulmonary venous hypertension (PVH), the alveolar-capillary unit may be irreversibly altered by a remodeling process characterized by excessive type IV collagen deposition, leading to a reduction in alveolar diffusion capacity.

Persistent passive elevation of pulmonary venous pressures can also induce histological changes in the pulmonary vasculature, such as arteriolar muscularization and formation of neointima and hypertrophy of the distal pulmonary arteries. It is important to note that these ultrastructural abnormalities of the pulmonary vessels that develop in chronic MR and other causes of left heart disease-associated pulmonary hypertension are distinctly different from those observed in pulmonary arterial (group 1) hypertension.

In addition to the histological changes, significant functional abnormalities in the pulmonary vasculature result from endothelial injury in the setting of PVH. Impairment and imbalance in endothelial production of nitric oxide (NO) and endothelin-1 (ET-1), key vasoactive mediators of pulmonary vascular resistance (PVR), leads to dysfunctional smooth muscle reactivity. Several studies have demonstrated the significance of NO and ET-1 levels in determining not only pulmonary vascular tone, but also overall prognosis in patients with pulmonary hypertension.

The final magnitude of pulmonary hypertension in patients with MR is determined by combination of a "passive" component resulting from PVH and a "precapillary" component driven by the extent of structural and functional changes in the pulmonary arterial vessels. Hemodynamic evaluation of patients with group 2 (left heart disease-associated) pulmonary hypertension reveals an "early" stage during which elevation of pulmonary arterial pressure (PAP) is primarily a result of high LAP. This stage is characterized by normal PVR and transpulmonary pressure gradient and is generally reversible. After a variable duration, the development of the above-mentioned progressive vascular changes leads to a "reactive" stage of pulmonary hypertension during which PAP increases disproportionately to increase in LAP. PVR is elevated during this stage, which may be either reversible or permanent. Even at this later stage of pulmonary hypertension, near-normalization of PAPs and PVR may be observed in many patients after successful mitral valve surgery. However long-term studies regarding the changes in pulmonary pressure after surgery are very limited. Persistence of significant pulmonary hypertension after surgery may be the result of residual MR,
relative mitral stenosis resulting from reduced mitral valve orifice area, prosthetic valve dysfunction, or persistent microvascular changes. Ultimately, the severity of pulmonary vascular pathology in MR and the rate of its progression and regression are also likely to be influenced by patient-related genetic susceptibility factors that are not yet fully understood. This is supported by the observation that many patients with long-standing, severe MR do not develop any elevation of PAP or PVR. However, no specific genetic linkages to group 2 pulmonary hypertension have been identified, unlike the association of polymorphisms in genes encoding bone morphogenetic protein receptor 2, activin receptor-like kinase type 1, and endoglin with group 1 pulmonary hypertension.

The pulmonary vasculature is normally a low-pressure, low-impedance system, which creates a low afterload on the right ventricle. Advanced or “reactive” pulmonary hypertension significantly increases right ventricular afterload and thus has a major effect on its function. In comparison to the left ventricle, the right ventricle is much more sensitive to prolonged pressure overload than volume overload as a result, in part, of certain morphologic features, such as myofiber orientation and differences in excitation-contraction coupling. Sustained elevation of afterload causes compensatory right ventricular (RV) myocardial hypertrophy in the initial phases, but can ultimately lead to maladaptive wall thinning, cavity dilation, tricuspid regurgitation, and reduction in contractility. Impairment of RV function and the resulting increase in right atrial pressure (RAP) can further exacerbate the HF syndrome by causing increase in release of brain natriuretic peptide and renal dysfunction as a result of venous congestion. The resulting expansion of intravascular volume lends to a vicious cycle of worsening MR, pulmonary venous congestion, and pulmonary hypertension. Several studies have demonstrated the key significance of RV dysfunction in determining the natural history and prognosis of patients with chronic MR and pulmonary hypertension.

Figure 2. Pathogenesis of pulmonary hypertension in mitral regurgitation. Chronic severe mitral regurgitation induces compensatory LV and LA dilation in the initial phase, but over time, leads to LV systolic and diastolic dysfunction, reduced LA compliance, and elevated LA pressure in the decompensated phase. Backward transmission of elevated left atrial pressures can cause disruption of the alveolar capillary complex with resultant pulmonary edema. Long-standing passive pulmonary hypertension resulting from venous congestion can lead to structural changes in the distal arterioles and endothelial injury with vascular functional abnormalities, which can then cause elevation in transpulmonary gradient and reactive pulmonary hypertension. Chronic right ventricular pressure overload resulting from pulmonary hypertension ultimately leads to cavity dilation and contractile dysfunction. AO indicates aorta; LA, left atrial; LV, left ventricle; LVEDP, left ventricular end diastolic pressure; PA, pulmonary artery; PV, pulmonary vascular; RA, right atrium; RV, right ventricle; TR, tricuspid regurgitant.
Diagnostic Evaluation

Echocardiography

Echocardiography has become established as the primary tool not only for evaluating the severity and etiology of MR, but also for the screening and monitoring of sequelae such as pulmonary hypertension (Table). Estimation of the PASP using Doppler-derived RV systolic pressure (RVSP) is the most commonly used noninvasive test for the diagnosis of pulmonary hypertension.32 Transthoracic Doppler echocardiography allows for measurement of the peak tricuspid regurgitant velocity (TRV), which is used to calculate the systolic pressure gradient between the RV and right atrium to estimate the PASP. Estimation of the PASP can lead to misclassification of its severity or even failure to identify it.32 Furthermore, even when RVSP is appropriately measured, it may belie the true severity of pulmonary hypertension in the presence of significant RV contractile dysfunction or low cardiac output.

When TRV measurement appears unreliable, the modified Bernoulli’s equation can be applied using the pulmonary regurgitant velocity (PRV) in early diastole and end diastole to calculate mean PAP and pulmonary artery diastolic pressure, respectively. However, PRV measurement often itself may be unreliable when a parallel Doppler intercept angle cannot be achieved. Other echocardiographic indices, such as RV outflow tract (RVOT) acceleration time and noninvasively estimated PVR may also be used to screen for pulmonary hypertension, but studies show variable degrees of correlation with invasively measured parameters.34,36

Table. Echocardiographic Evaluation in Patients With Pulmonary Hypertension Resulting From Severe Mitral Regurgitation

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Normal Range</th>
<th>Pulmonary Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-axis view of LV</td>
<td>LV end-diastolic diameter, cm</td>
<td>4.2 to 5.9 (males); 3.9 to 5.3 (females)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>LV end-systolic diameter, cm</td>
<td>2.1 to 4.0 (males); 2.4 to 4.0 (females)</td>
<td>↑</td>
</tr>
<tr>
<td>Long-axis view of the RV inflow tract</td>
<td>Basal diameter of RV, cm</td>
<td>3.7 to 5.4</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Tricuspid annulus, cm</td>
<td>1.3 to 2.8</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Tricuspid regurgitant velocity, m/s</td>
<td>&lt;2.6</td>
<td>↑</td>
</tr>
<tr>
<td>Long- and short-axis views of RVOT</td>
<td>RVOT, cm</td>
<td>1.7 to 2.3</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Main pulmonary trunk, cm</td>
<td>1.5 to 2.1</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>RV outflow acceleration time, ms</td>
<td>&gt;110</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>Pulmonary regurgitant velocity (beginning of diastole), m/s</td>
<td>&lt;1</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Pulmonary regurgitant velocity (end diastole), m/s</td>
<td>&lt;1</td>
<td>↑</td>
</tr>
<tr>
<td>Apical 4-chamber view (2D echo)</td>
<td>Basal diameter of RV, cm</td>
<td>2.0 to 2.8</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>RV end-diastolic area, cm²</td>
<td>11 to 28</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>RV end-systolic area, cm²</td>
<td>7.5 to 16</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Right atrial area (end-systole), cm²</td>
<td>13.5±2</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>RA volume index, mL/m²</td>
<td>&lt;34 (males); &lt;27 (females)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Tricuspid annulus, cm</td>
<td>1.3 to 2.8</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Right ventricular fractional area change, %</td>
<td>32 to 60</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>LV end-diastolic volume, cm³</td>
<td>67 to 155 (males); 56 to 104 (females)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>LV end-systolic volume, cm³</td>
<td>22 to 58 (males); 19 to 49 (females)</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Left atrial area (end-systole), cm²</td>
<td>&lt;20</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>LA volume index, mL/m²</td>
<td>&lt;29</td>
<td>↑</td>
</tr>
<tr>
<td>Apical 4-chamber view (Doppler echo)</td>
<td>Tricuspid regurgitant velocity, m/s</td>
<td>&lt;2.6</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>Deceleration time–tricuspid inflow, ms</td>
<td>144 to 244</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>RV MPI (Tei index)</td>
<td>0.28</td>
<td>↑</td>
</tr>
<tr>
<td></td>
<td>TAPSE, mm</td>
<td>&gt;20</td>
<td>↓</td>
</tr>
<tr>
<td></td>
<td>IVRT (TDI RV free wall), ms</td>
<td>&gt;75</td>
<td>↑</td>
</tr>
</tbody>
</table>

† indicates increased in pulmonary hypertension; ↓, decreased in pulmonary hypertension; IVRT, isovolumic relaxation time; LA, left atrial; LV, left ventricle; MPI, myocardial performance index; RA, right atrium; RV, right ventricle; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging.

Reproduced with permission of the European Respiratory Society from Howard et al.32
Assessment of RV structure and function is an important part of the echocardiographic evaluation of patients with pulmonary hypertension resulting from MR because of its added prognostic significance. Tissue Doppler measurement of the tricuspid annular plane systolic excursion (TAPSE) provides a quantitative index of RV systolic function and has been shown to be predictive of perioperative and long-term mortality risk. The presence of significant tricuspid regurgitation (3+ or greater) and elevated indexed right atrial area are also associated with increased risk of perioperative mortality. RV eccentricity index, a quantitative measure of RV remodeling, has been shown to predict long-term mortality in patients with PAH, but its value in patients with MR has not been studied.

Exercise echocardiography can also provide valuable information in the evaluation of patients with MR. Because of the adverse effect of resting pulmonary hypertension and manifest left ventricular dysfunction (LVD) on operative mortality, there is increased emphasis on early detection of patients at risk of developing these sequelae of chronic MR. Exercise-induced increase in PASP and MR has been shown to be associated with occult LVD and reduced symptom-free survival. Other indices of LV function during exercise, such as end-systolic volume (ESV) and contractile reserve (exercise-induced increase in EF or longitudinal strain) appear to predict postoperative ventricular function more accurately than resting indices. Thus, in addition to providing an objective assessment of functional capacity, exercise echocardiography may help identify asymptomatic patients with severe MR and apparently normal resting LV function in the transitional phase who would benefit from immediate referral to mitral valve surgery.

Invasive Hemodynamic Measurements

Invasive measurement of PAPs through right heart catheterization is essential to confirm the diagnosis and severity of pulmonary hypertension. Consensus guidelines define pulmonary hypertension as a mean PAP >25 mm Hg. Pulmonary hypertension resulting from left heart diseases (pulmonary hypertension-LHD or group 2 pulmonary hypertension) such as MR is distinguished from PAH (group 1 pulmonary hypertension) by the presence of pulmonary capillary wedge pressure (PCWP) >15 mm Hg. PCWP is widely considered to be a surrogate measure of LV end diastolic pressure (LVEDP), but data supporting this assumption in patients with pulmonary hypertension are scant. In a large study of over 4000 patients with pulmonary hypertension, almost 50% of patients with normal PCWP were found to have elevated LVEDP. Thus, if PCWP is found to be <15 mm Hg, despite high clinical suspicion of elevated left-sided filling pressures, confirmation of LVEDP through left heart catheterization may be required. Volume or exercise challenges during right heart catheterization may be used to unmask postcapillary pulmonary hypertension in patients with borderline PCWP or LVEDP (13 to 18 mm Hg) at rest resulting from aggressive preload reduction with diuretic therapy. If PCWP or LVEDP is found to be normal, despite thorough evaluation in a patient with severe MR, a search for alternate causes of pulmonary hypertension should be performed. Right heart catheterization also allows for differentiation of “passive” and “reactive” pulmonary hypertension by calculation of the transpulmonary gradient (TPG), which is defined as the difference between mean PAP and mean PCWP. In passive pulmonary hypertension, the TPG is normal (<12 mm Hg), but is elevated (>12 mm Hg) in those with reactive or out-of-proportion pulmonary hypertension.

Vasoreactivity testing to evaluate for reduction in mean PAP with agents, such as NO or nitroprusside, is an integral part of the assessment of patients with PAH (group 1 pulmonary hypertension). However, its value in preoperative assessment of patients with pulmonary hypertension resulting from MR is unclear. Vasoreactivity testing in such patients is not recommended because of concern for increase in left-sided filling pressures and precipitation of pulmonary edema. Patients with pulmonary hypertension resulting from MR were excluded from studies that led to U.S. Food and Drug Administration approval of several pulmonary vasodilators for use in PAH. However recent studies have shown that inhaled prostacyclins and inhaled NO can be used to reduce PAPs, PVR, and improve cardiac output in patients with pulmonary hypertension resulting from MVD after surgery. Though short-term use of these pulmonary vasodilators in the postoperative period appears safe, careful monitoring of PCWP is necessary during administration to avoid development of pulmonary edema.

Advanced Hemodynamic Assessment of Ventricular Function

As discussed in more detail below, there is an increasing emphasis on referral of patients for surgical correction of severe MR before the development of sequelae such as pulmonary hypertension and ventricular dysfunction to reduce perioperative morbidity and mortality. Unfortunately, the standard methods of measuring LV function, such as EF, fractional shortening, and so on, are highly load dependent. Thus, in the presence of increased preload and reduced afterload, such as in the compensated phase of MR, monitoring these indices of ventricular function may not allow detection of early, subclinical LV contractile dysfunction before development of overt, irreversible systolic dysfunction and pulmonary hypertension.

By contrast, the end-systolic pressure-volume relationship (ESPVR) has been shown to be a load-independent measure of
Pulmonary Hypertension in Mitral Regurgitation  
Patel et al

The negative prognostic significance of pulmonary hypertension in patients with MR is well known, but incompletely studied. The 1998 ACC/AHA Valve Disease guidelines specified the presence of pulmonary hypertension (defined as systolic pressure $>50$ mm Hg at rest or $>60$ mm Hg with exercise) as an indication (class IIA) for surgery in patients with asymptomatic severe MR based on only one small study, which showed that mild pulmonary hypertension (mean PAP $>20$ mm Hg) was associated with increased postoperative LV enlargement.\textsuperscript{52,53} The 2006 guideline update continued this recommendation, but did not provide additional support. Recently, however, several studies have demonstrated the negative implications of pulmonary hypertension in MR not only in terms of natural history, but also in terms of perioperative outcomes. Yang et al demonstrated that preoperative pulmonary hypertension (PASP $>30$ mm Hg) is associated with significant reduction in postoperative left ventricular ejection fraction (LVEF) in patients with degenerative MR and normal preoperative LVEF.\textsuperscript{54} Of note, the severity of pulmonary hypertension was shown to correlate with degree of reduction in postoperative LVEF. Le Tourneau et al. showed that, in patients with chronic degenerative MR, pulmonary hypertension (PASP $>50$ mm Hg) was associated with lower postoperative LVEF and higher risk of persistence of pulmonary hypertension as well as symptoms after mitral valve surgery.\textsuperscript{55} Kainuma et al. showed that, in patients with functional MR undergoing restrictive mitral annuloplasty, pulmonary hypertension was associated with increased rates of long-term mortality and readmission for HF.\textsuperscript{56} In a large, single-center study, Ghoreishi et al. showed that, in patients with degenerative MR and pulmonary hypertension (PASP $>40$ mm Hg) undergoing mitral valve surgery (98% underwent mitral valve repair), even mildly elevated preoperative PASP correlated with increased operative mortality, postoperative LVD, as well as long-term mortality.\textsuperscript{57} Similarly, another large, multicenter, international study also demonstrated that pulmonary hypertension in patients with MR approximately doubles the risk of HF and death after diagnosis and that surgery does not completely abolish the risk of adverse events once pulmonary hypertension is established.\textsuperscript{10}

The recent evidence of the negative prognostic implications of pulmonary hypertension in MR has rekindled the debate of whether asymptomatic patients with repairable valves should be referred to surgery in the early stages of pulmonary hypertension (PASP 40 to 50 mm Hg) or even before development of pulmonary hypertension. Improvements in surgical technology and technique over the past several decades have led to high rates of successful outcome with low mortality risk in patients undergoing mitral valve repair, especially at high-volume surgical centers in the absence of comorbidities, such as LVD, pulmonary hypertension, or atrial fibrillation. Kang et al. showed that, in patients with asymptomatic severe MR and normal LVEF, early mitral valve repair was associated with reduced long-term mortality and HF hospitalization, compared to conservative management.\textsuperscript{58}

**Implications for Management**

The negative prognostic significance of pulmonary hypertension in patients with MR is well known, but incompletely studied. The 1998 ACC/AHA Valve Disease guidelines specified the presence of pulmonary hypertension (defined as systolic pressure $>50$ mm Hg at rest or $>60$ mm Hg with exercise) as an indication (class IIA) for surgery in patients with asymptomatic severe MR based on only one small study, which showed that mild pulmonary hypertension (mean PAP $>20$ mm Hg) was associated with increased postoperative LV enlargement.\textsuperscript{52,53} The 2006 guideline update continued this recommendation, but did not provide additional support. Recently, however, several studies have demonstrated the negative implications of pulmonary hypertension in MR not only in terms of natural history, but also in terms of perioperative outcomes. Yang et al demonstrated that preoperative pulmonary hypertension (PASP $>30$ mm Hg) is associated with significant reduction in postoperative left ventricular ejection fraction (LVEF) in patients with degenerative MR and normal preoperative LVEF.\textsuperscript{54} Of note, the severity of pulmonary hypertension was shown to correlate with degree of reduction in postoperative LVEF. Le Tourneau et al. showed that, in patients with chronic degenerative MR, pulmonary hypertension (PASP $>50$ mm Hg) was associated with lower postoperative LVEF and higher risk of persistence of pulmonary hypertension as well as symptoms after mitral valve surgery.\textsuperscript{55} Kainuma et al. showed that, in patients with functional MR undergoing restrictive mitral annuloplasty, pulmonary hypertension was associated with increased rates of long-term mortality and readmission for HF.\textsuperscript{56} In a large, single-center study, Ghoreishi et al. showed that, in patients with degenerative MR and pulmonary hypertension (PASP $>40$ mm Hg) undergoing mitral valve surgery (98% underwent mitral valve repair), even mildly elevated preoperative PASP correlated with increased operative mortality, postoperative LVD, as well as long-term mortality.\textsuperscript{57} Similarly, another large, multicenter, international study also demonstrated that pulmonary hypertension in patients with MR approximately doubles the risk of HF and death after diagnosis and that surgery does not completely abolish the risk of adverse events once pulmonary hypertension is established.\textsuperscript{10}

The recent evidence of the negative prognostic implications of pulmonary hypertension in MR has rekindled the debate of whether asymptomatic patients with repairable valves should be referred to surgery in the early stages of pulmonary hypertension (PASP 40 to 50 mm Hg) or even before development of pulmonary hypertension. Improvements in surgical technology and technique over the past several decades have led to high rates of successful outcome with low mortality risk in patients undergoing mitral valve repair, especially at high-volume surgical centers in the absence of comorbidities, such as LVD, pulmonary hypertension, or atrial fibrillation. Kang et al. showed that, in patients with asymptomatic severe MR and normal LVEF, early mitral valve repair was associated with reduced long-term mortality and HF hospitalization, compared to conservative management.\textsuperscript{58}
The effect of pulmonary hypertension on perioperative morbidity and mortality also inspires consideration of the associated factors that are predictive of the highest risk of adverse perioperative outcomes, which would make surgery prohibitively hazardous. Corciowi et al. showed that pulmonary hypertension increased perioperative mortality in patients with MR undergoing mitral valve surgery and receiver operative characteristic curves identified PASP >65 mm Hg to have the highest sensitivity and specificity for risk of perioperative death.37 Similar thresholds of RV and LV systolic dysfunction and dimensions that define the highest risk for adverse perioperative outcome need to be defined. The perioperative risk of morbidity and mortality is also significantly influenced by the type of mitral valve surgery in patients with pulmonary hypertension. Yang et al showed that mitral valve replacement was associated with greater reduction in postoperative LVEF than mitral valve repair.54 Le Tourneau et al showed that mitral valve replacement was associated with higher immediate postoperative mortality than mitral valve repair (6.4% versus 1%), though intraoperative mortality was not significantly different.55 Several studies have clearly established that mitral valve replacement without chordal preservation leads to alteration of LV geometry and reduction of systolic function and therefore should be avoided in patients with pulmonary hypertension, especially when severe.

The role of percutaneous mitral valve repair in patients with MR is still being defined. At present, there are 2 main percutaneous approaches to correct mitral regurgitation. The edge-to-edge repair using a percutaneously implanted clip (ie, MitraClip™) is the approach with the largest clinical and research experience. Coronary sinus annuloplasty (ie, Viking device) is another approach being studied in patients with functional MR. Recently, investigators of the EVEREST II trial, which randomized patients with MR to percutaneous repair (using MitraClip) or conventional mitral surgery, showed that percutaneous repair was associated with reduced rate of adverse periprocedural events and similar improvements in clinical outcomes, compared to surgery, albeit with lower efficacy in reducing MR.55 Percutaneous mitral valve repair may thus be an attractive option in patients with MR who are deemed to have a prohibitively high risk for adverse events with conventional surgery, such as some with severe pulmonary hypertension. The EVEREST II trial, however, did not evaluate outcomes based on preoperative PAPs, and thus further research is needed to define the role of percutaneous mitral valve repair in patients with pulmonary hypertension.

In summary, pulmonary hypertension is a well-known, but incompletely studied, complication of severe MR. The pathogenesis of pulmonary hypertension in patients with severe MR has a passive component resulting from elevation in LAPs as well as a reactive component resulting from structural and functional vascular changes. Individual genetic and constitutional risk factors likely play a significant role in the development of pulmonary hypertension, but are poorly understood at present. Though many patients experience improvement in pulmonary pressures after surgery, there is a paucity of data regarding the long-term evolution of pulmonary vascular changes. Echocardiography is essential to not only diagnose pulmonary hypertension, but also to provide prognostic information, such as RV structure and function. Recent evidence shows that pulmonary hypertension is not only a poor prognostic indicator under conservative management, but also portends adverse perioperative outcomes. Further research is needed to identify risk factors associated with poor outcomes after surgery with pulmonary hypertension resulting from severe mitral regurgitation.

Disclosures

None.

References


Key Words: mitral regurgitation • mitral valve regurgitation • pulmonary hypertension
Pulmonary Hypertension in Mitral Regurgitation
Harsh Patel, Milind Desai, E. Murat Tuzcu, Brian Griffin and Samir Kapadia

*J Am Heart Assoc.* 2014;3:e000748; originally published August 7, 2014;
doi: 10.1161/JAHA.113.000748

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/3/4/e000748